▶ 調査レポート

医薬品有効成分の世界市場

• 英文タイトル:Global Market Study on Active Pharmaceutical Ingredients: Small Molecules API Segment Anticipated to Create Significant Growth Opportunities During 2017 - 2025

Persistence Market Researchが調査・発行した産業分析レポートです。医薬品有効成分の世界市場 / Global Market Study on Active Pharmaceutical Ingredients: Small Molecules API Segment Anticipated to Create Significant Growth Opportunities During 2017 - 2025 / B-PMR-343資料のイメージです。• レポートコード:B-PMR-343
• 出版社/出版日:Persistence Market Research / 2017年6月27日
• レポート形態:英文、PDF、256ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:医療・バイオ
• 販売価格(消費税別)
  Individual(1名、印刷不可)¥509,600 (USD4,900)▷ お問い合わせ
  Multi User(5名)¥790,400 (USD7,600)▷ お問い合わせ
  Corporate User¥1,102,400 (USD10,600)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査レポートでは、医薬品有効成分の世界市場について調査・分析し、関連企業情報、産業分析、医薬品有効成分の世界市場規模、市場動向、セグメント別市場分析、地域別市場規模(欧州、アメリカ、アジアなど)、市場予測データを含め、以下の構成でお届けいたします。

An active pharmaceutical ingredient is a substance or a combination thereof used in a pharmaceutical product for providing direct access to the diagnosis, prevention, cure, or treatment of diseases or to have a direct impact in correcting, modifying, or restoring physiological functions in humans. Persistence Market Research has studied the global active pharmaceutical ingredients market in its report titled “Active Pharmaceutical Ingredients Market: Global Industry Analysis and Forecast, 2017 – 2025’’. The report includes revenue of the API manufacturers i.e. for both outsourced and in-house manufacturing. However, the report doesn’t consider API revenue that has not been mentioned herein.
Active Pharmaceutical Ingredients Market: Taxonomy

Region

North America
Latin America
Europe
APAC
RoW
API Type

Small Molecules
Controlled Substances
Natural Opioids
Semi-synthetic/Synthetic Opioids
Non-Controlled Substances
NSAIDs
Anti-infective
Antimicrobial
Oral anti-diabetics
Anti-hypertensive
Others
HPAPI
Peptides & Oligonucleotides
Carbohydrate Drugs
Steroidal Drugs
Certain assumptions have been made and a few acronyms have been used to prepare the active pharmaceutical ingredients market report. These have been adequately explained in a section that readers can acquaint themselves with to ensure that they understand the active pharmaceutical ingredients market with all of its nuances and technicalities.

One-of-a-kind research methodology used to prepare all research reports

The research methodology adopted by PMR to create reports such as the active pharmaceutical ingredients market report is world class. The team of diverse, knowledgeable analysts begin their study with rigorous primary and secondary research in the active pharmaceutical ingredients market. A market player list that includes each node of the value chain is devised and a questionnaire that assists in the extraction of all the required data is prepared. After the information has been gathered, it is exhaustively validated using the triangulation method that combines the opinions of PMR experts with both primary and secondary research data. The final data is thoroughly scrutinized to obtain all the necessary insights concerning the active pharmaceutical ingredients market.

The active pharmaceutical ingredients market is marked by cutthroat competition and it is challenging but not impossible for any new entrants seeking to enter this lucrative market. Potential stakeholders are highly advised to refer to the competition landscape chapter of the active pharmaceutical ingredients market report. Here, PMR has profiled several prominent organizations active in the global active pharmaceutical ingredients market. The key players for small molecule API CDMO, Peptide API, Oligonucleotide API, Steroid API, Carbohydrate API, HPAPI, and controlled substances have each been analyzed in a different section. It is possible to carry out an in-depth competition SWOT analysis and potential entrants can decide which segment they wish to target based on their inherent strengths and the weaknesses of the immediate competition.

It is not surprising that there is a heavy regulatory oversight in a market as critical to human life as the active pharmaceutical ingredients market. A highly important section of the active pharmaceutical ingredients market report has specifically spoken about the major deals and regulations that pertain to API CDMO. It is followed by the drug pipeline analysis of Oligonucleotides, Peptides, Steroidal drugs, and High Potency API Drugs. The primary respondents by each region and their outlooks follow. The global active pharmaceutical ingredients market has been divided into five broad geographic regions viz. APAC, RoW, Europe, Latin America, and North America; each of which has its own section in the active pharmaceutical ingredients market report. The report provides the market value share and BPS analysis of the largest regional markets and also gives the market attractiveness on a country basis. Key trends and regulations that pertain to a specific region or country within that region complete this informative section.

The active pharmaceutical ingredients market report has a preface at the outset that is a brief glance at the active pharmaceutical ingredients market. It is closely related to (and followed by) the market definition as well as the taxonomy of the active pharmaceutical ingredients market. PMR analysts have studied the active pharmaceutical ingredients market for a period of eight years from 2017 to 2025 and have formed their opinions and recommendations based on current and future anticipated trends in the active pharmaceutical ingredients market. These have been detailed in the form of geographic regions and segments to target with a differentiating strategy to stand above all others in the active pharmaceutical ingredients market.

The market dynamics of a market as volatile as the active pharmaceutical ingredients market cannot be overlooked. The drivers, restraints, opportunities, and trends that are predicted to have an outsized impact on the active pharmaceutical ingredients market are highlighted in this section and report readers would do well to peruse them to make critical decision-making that little bit easier.

レポート目次

1. Preface

2. Research Methodology

3. Assumptions & Acronyms Used

4. Market Definition

5. Market Taxonomy

6. Executive Summary

7. Market Dynamics
7.1. Macro-economic Dynamics
7.2. Drivers
7.3. Restraints
7.4. Opportunities
7.5. Trends

8. Major Deals and Regulations: API CDMO

9. Drug Pipeline Analysis
9.1. Oligonucleotide Drug Pipeline Analysis
9.2. Peptides Drug Pipeline Analysis
9.3. Steroidal Drug Pipeline Analysis
9.4. High Potency API Drug Pipeline Analysis

10. Primary Responses and Interpretation
10.1. Primary Respondents by Region
10.2. Primary (KOL) Outlooks

11. Global Active Pharmaceutical Ingredients Market, by API Type, 2011-2025
11.1. Overview
11.2. Market Value Share & BPS Analysis, by API Type, 2011- 2025
11.3. Market Historic Market Value (US$ Mn) & Y-o-Y Growth (%), by API Type, 2011- 2025
11.3.1. Small Molecules
11.3.1.1. Controlled Substances
11.3.1.1.1. Natural Opioids
11.3.1.1.2. Semi-synthetic/Synthetic Opioids
11.3.1.2. Non-Controlled Substances
11.3.1.2.1. NSAIDs
11.3.1.2.2. Anti-infective
11.3.1.2.3. Antimicrobial
11.3.1.2.4. Oral anti-diabetics
11.3.1.2.5. Anti-hypertensive
11.3.1.2.6. Others
11.3.1.3. HPAPI
11.3.2. Peptides & Oligonucleotides
11.3.3. Carbohydrate Drugs
11.3.4. Steroidal Drugs
11.4. Market Attractiveness Analysis by API Type

12. Global Active Pharmaceutical Ingredients Market, by Region, 2011-2025
12.1. Overview
12.2. Market Value Share & BPS Analysis, by Region, 2011- 2025
12.3. Market Historic Market Value (US$ Mn) & Y-o-Y Growth (%), by Region, 2011- 2025
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. Asia Pacific
12.3.5. Rest of World
12.4. Market Attractiveness Analysis by Region

13. North America Active Pharmaceutical Ingredients Market Revenue, 2011- 2025
13.1. Overview
13.2. Market Value Share & BPS Analysis, by API Type, 2011- 2025
13.3. Market Historic Market Value (US$ Mn) & Y-o-Y Growth (%), by API Type, 2011- 2025
13.3.1. Small Molecules
13.3.1.1. Controlled Substances
13.3.1.1.1. Natural Opioids
13.3.1.1.2. Semi-synthetic/Synthetic Opioids
13.3.1.2. Non-Controlled Substances
13.3.1.2.1. NSAIDs
13.3.1.2.2. Anti-infective
13.3.1.2.3. Antimicrobial
13.3.1.2.4. Oral anti-diabetics
13.3.1.2.5. Anti-hypertensive
13.3.1.2.6. Others
13.3.1.3. HPAPI
13.3.2. Peptides & Oligonucleotides
13.3.3. Carbohydrate Drugs
13.3.4. Steroidal Drugs
13.4. Market Attractiveness Analysis by Country
13.5. North America API Market Value, by API Type, 2011–2025
13.6. North America API Market Value, by Country, 2011–2025
13.7. Key Market Trends: North America API Market

14. Latin America Active Pharmaceutical Ingredients Market Revenue, 2011- 2025
14.1. Overview
14.2. Market Value Share & BPS Analysis, by API Type, 2011- 2025
14.3. Market Historic Market Value (US$ Mn) & Y-o-Y Growth (%), by API Type, 2011- 2025
14.3.1. Small Molecules
14.3.1.1. Controlled Substances
14.3.1.1.1. Natural Opioids
14.3.1.1.2. Semi-synthetic/Synthetic Opioids
14.3.1.2. Non-Controlled Substances
14.3.1.2.1. NSAIDs
14.3.1.2.2. Anti-infective
14.3.1.2.3. Antimicrobial
14.3.1.2.4. Oral anti-diabetics
14.3.1.2.5. Anti-hypertensive
14.3.1.2.6. Others
14.3.1.3. HPAPI
14.3.2. Peptides & Oligonucleotides
14.3.3. Carbohydrate Drugs
14.3.4. Steroidal Drugs
14.4. Market Attractiveness Analysis by Country
14.5. Latin America API Market Value, by API Type, 2011–2025
14.6. Latin America API Market Value, by Country, 2011–2025
14.7. Key Market Trends: Latin America API Market

15. Europe Active Pharmaceutical Ingredients Market Revenue, 2011- 2025
15.1. Overview
15.2. Market Value Share & BPS Analysis, by API Type, 2011- 2025
15.3. Market Historic Market Value (US$ Mn) & Y-o-Y Growth (%), by API Type, 2011- 2025
15.3.1. Small Molecules
15.3.1.1. Controlled Substances
15.3.1.1.1. Natural Opioids
15.3.1.1.2. Semi-synthetic/Synthetic Opioids
15.3.1.2. Non-Controlled Substances
15.3.1.2.1. NSAIDs
15.3.1.2.2. Anti-infective
15.3.1.2.3. Antimicrobial
15.3.1.2.4. Oral anti-diabetics
15.3.1.2.5. Anti-hypertensive
15.3.1.2.6. Others
15.3.1.3. HPAPI
15.3.2. Peptides & Oligonucleotides
15.3.3. Carbohydrate Drugs
15.3.4. Steroidal Drugs
15.4. Market Attractiveness Analysis by Country
15.5. Europe API Market Value, by API Type, 2011–2025
15.6. Europe API Market Value, by Country, 2011–2025
15.7. Key Market Trends: Europe API Market

16. APAC Active Pharmaceutical Ingredients Market Revenue, 2011- 2025
16.1. Overview
16.2. Market Value Share & BPS Analysis, by API Type, 2011- 2025
16.3. Market Historic Market Value (US$ Mn) & Y-o-Y Growth (%), by API Type, 2011- 2025
16.3.1. Small Molecules
16.3.1.1. Controlled Substances
16.3.1.1.1. Natural Opioids
16.3.1.1.2. Semi-synthetic/Synthetic Opioids
16.3.1.2. Non-Controlled Substances
16.3.1.2.1. NSAIDs
16.3.1.2.2. Anti-infective
16.3.1.2.3. Antimicrobial
16.3.1.2.4. Oral anti-diabetics
16.3.1.2.5. Anti-hypertensive
16.3.1.2.6. Others
16.3.1.3. HPAPI
16.3.2. Peptides & Oligonucleotides
16.3.3. Carbohydrate Drugs
16.3.4. Steroidal Drugs
16.4. Market Attractiveness Analysis by Country
16.5. APAC API Market Value, by API Type, 2011–2025
16.6. APAC API Market Value, by Country, 2011–2025
16.7. Key Market Trends: APAC API Market

17. Rest of World Active Pharmaceutical Ingredients Market Revenue, 2011- 2025
17.1. Overview
17.2. Market Value Share & BPS Analysis, by API Type, 2011- 2025
17.3. Market Historic Market Value (US$ Mn) & Y-o-Y Growth (%), by API Type, 2011- 2025
17.3.1. Small Molecules
17.3.1.1. Controlled Substances
17.3.1.1.1. Natural Opioids
17.3.1.1.2. Semi-synthetic/Synthetic Opioids
17.3.1.2. Non-Controlled Substances
17.3.1.2.1. NSAIDs
17.3.1.2.2. Anti-infective
17.3.1.2.3. Antimicrobial
17.3.1.2.4. Oral anti-diabetics
17.3.1.2.5. Anti-hypertensive
17.3.1.2.6. Others
17.3.1.3. HPAPI
17.3.2. Peptides & Oligonucleotides
17.3.3. Carbohydrate Drugs
17.3.4. Steroidal Drugs
17.4. Market Attractiveness Analysis by Country
17.5. RoW API Market Value, by API Type, 2011–2025
17.6. RoW API Market Value, by Country, 2011–2025
17.7. Key Market Trends: RoW API Market

18. Company Profile
18.1. Small Molecule API CDMO
18.1.1. Johnson Matthey
18.1.2. Siegfried
18.1.3. Almac
18.2. Peptide API
18.2.1. PolyPeptide Laboratories
18.2.2. AmbioPharm, Inc.
18.2.3. Corden Pharma
18.2.4. Pepscan
18.2.5. BCN peptide
18.2.6. Provence Technologies Groups
18.2.7. SennChemicals AG
18.3. Oligonucleotide API
18.3.1. Avecia OligoMedicines
18.3.2. Santaris Pharma – acquired by Roche in 2014
18.3.3. ST Pharm Oligo Center
18.3.4. Cepia Sanofi
18.3.5. Biospring
18.4. Steroid API
18.4.1. Pfizer CenterSource
18.4.2. Symbiotec Pharma Lab Pvt. Ltd.
18.4.3. Gadea Grupo Farmacéutico
18.4.4. STEROID S.p.A.
18.4.5. Dolder AG
18.4.6. Dalton Pharma Services
18.4.7. FarmaBios Spa
18.5. Carbohydrate API
18.5.1. Dextra Laboratories Limited
18.5.2. GlycoSyn
18.5.3. Inalco Pharma
18.5.4. Sussex Research
18.5.5. Pfanstiehl, Inc.
18.6. Controlled Substance
18.6.1. Noramco, Inc.
18.6.2. Johnson Matthey
18.6.3. Siegfried
18.6.4. Rhodes Technologies
18.7. HPAPI
18.7.1. Ash Stevens
18.7.2. Fermion (public)
18.7.3. FARMHISPANIA GROUP
18.7.4. Olon SpA
18.7.5. Lonza Group

List of Tables

Table 01: Global Pharmaceutical Market Indicators
Table 02: Active Pharmaceutical Ingredient Market Value (US$ Bn), by API Type, 2011-2025
Table 03: North America Active Pharmaceutical Ingredient Market Value (US$ Bn), by Region, 2011–2025
Table 04: North America Active Pharmaceutical Ingredient Market Value (US$ Bn), by API Type, 2011–2025
Table 05: North America Active Pharmaceutical Ingredient Market Value (US$ Bn), by Country, 2011–2025
Table 06: Latin America Active Pharmaceutical Ingredient Market Value (US$ Bn), by API Type, 2011–2025
Table 07: Latin America Active Pharmaceutical Ingredient Market Value (US$ Bn), by Country, 2011–2025
Table 08: Europe Active Pharmaceutical Ingredient Market Value (US$ Bn), by API Type, 2011–2025
Table 09: Europe Active Pharmaceutical Ingredient Market Value (US$ Bn), by Country, 2011–2025
Table 10: Asia Pacific Active Pharmaceutical Ingredient Market Value (US$ Bn), by API Type, 2011–2025
Table 11: Asia Pacific Active Pharmaceutical Ingredient Market Value (US$ Bn), by Country, 2011–2025
Table 12: Rest of World Active Pharmaceutical Ingredient Market Value (US$ Bn), by API Type, 2011–2025
Table 13: Rest of World Active Pharmaceutical Ingredient Market Value (US$ Bn), by Country, 2011–2025